While having a single BP acquiring LymPro would certainly benefit shareholders in both companies, I feel this approach would not benefit the AD community, especially if the BP chose not to market the test to competitors to aid in their research efforts. One would hope that any LymPro acquisition deal our company might make would be with a contractual requirement the acquiring company make the test available to competitors at some level so as to not restrict research for a cure for AD.